Skip to main content
. 2022 Oct 29;6(6):pkac075. doi: 10.1093/jncics/pkac075

Figure 1.

Figure 1.

Study design. CaM = calmangafodipir; CIPN = chemotherapy-induced peripheral neuropathy; mFOLFOX6 = modified folinic acid, 5-fluorouracil, and oxaliplatin chemotherapy regimen; POLAR-A = Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in adjuvant setting; POLAR-M = Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in metastatic setting.